|Bid||69.37 x 1300|
|Ask||69.35 x 1400|
|Day's Range||69.15 - 69.73|
|52 Week Range||62.52 - 78.38|
|Beta (3Y Monthly)||0.89|
|PE Ratio (TTM)||42.11|
|Earnings Date||Oct 31, 2018|
|Forward Dividend & Yield||0.76 (1.09%)|
|1y Target Est||80.29|
Strong performance in the Subscription revenues segment drives Medidata???s (MDSO) results in Q3. Professional services also posted steady growth.
Of the total 28 analysts covering Stryker (SYK) in October 2018, 19 analysts have given the stock a “buy” or higher rating, and nine analysts have given Stryker a “hold” rating. The mean rating for Stryker is 1.93 with a target price of $187.27, which implies an upside potential of 8.2% over Stryker’s closing price of $173.1 on October 18. In comparison, peers Baxter International (BAX), Boston Scientific (BSX), and Zimmer Biomet Holdings (ZBH) have a mean rating of 2.41x, 1.52x, and 2.31x, respectively, and a target price of $79.79, $41.57, and $136.92, respectively.
Mallinckrodt (MNK) gets $26 million for additional funding from BARDA for pediatric studies of StrataGraft skin tissue in thermal burns.
Stryker’s (SYK) gross income is expected to increase by 8.63% from $1.98 billion in the third quarter of 2017 to $2.16 billion in the third quarter of 2018. Stryker’s gross margin is expected to expand from 66.03% for the third quarter of fiscal 2017 to 66.18% for the third quarter of fiscal 2018. Stryker’s gross margins for fiscal 2018 and 2019 are expected at 66.27% and 66.48%, respectively.
Baxter International Inc. (BAX), a leading global medical products company, will highlight its latest innovations in critical care at the 2018 European Society of Intensive Care Medicine (ESICM) congress in Paris from Oct. 20-24. The company will also sponsor two symposia to address top issues facing critical care clinicians: reducing IV infusion medication programming errors and innovation in continuous renal replacement therapy (CRRT) and extracorporeal removal of inflammatory mediators in sepsis management.
Of the total 25 analysts covering Boston Scientific (BSX) in October 2018, 22 analysts have given Boston Scientific a “buy” or higher rating, and three analysts have given Boston Scientific a “hold” rating. The mean rating for Boston Scientific is 1.52 with a target price of $41.57, which implies an upside potential of 9.4% over Boston Scientific’s closing price of $38.0 on October 17, 2018.
Boston Scientific’s (BSX) gross income is expected to increase by 9.26% from $1.58 billion in the third quarter of fiscal 2017 to $1.73 billion in the third quarter of fiscal 2018. Its gross margin is expected to expand from 71.33% for the third quarter of fiscal 2017 to 71.95% for the third quarter of fiscal 2018.
Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
NEW YORK, Oct. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Today the American Society for Parenteral and Enteral Nutrition (ASPEN), an organization which drives the science and practice of clinical nutrition, and Baxter International Inc. (BAX), a global leader in clinical nutrition, launched an educational video series on the appropriate use of parenteral nutrition (PN), as part of the organizations’ “SmartPN” collaboration to help reduce clinical malnutrition that was announced last year.
Suvretta Capital Management is a young New York-based hedge fund founded by its current portfolio manager, Aaron Cowen, in 2012. Prior to founding Suvretta, Mr. Cowen honed his investment acumen working at two acclaimed large hedge funds: as a portfolio manager at Soros Fund Management, and as a CIO at SAC Capital. Prior to those positions, […]
On October 4, Abbott Laboratories (ABT) ended the trading day at $71.82, down ~0.31% from the previous day’s close. The stock registered a 52-week high of $74.15 on October 1. Throughout the week, it’s fallen ~1.6%.
Abbott Laboratories (ABT) offers market-leading products and solutions across its Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals operating segments.
Baxter International Inc. , a leading global medical products company, will present at the 27th Annual Credit Suisse Healthcare Conference in Scottsdale, Ariz. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present on Wednesday, November 14, 2018 at 8:00 a.m.
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.